China Dips Its Toes in Disruptive IVD Tech
Executive Summary
The number of Chinese IVD companies exhibiting at the 2015 American Association for Clinical Chemistry Annual Meeting (AACC) & Clinical Lab Expo (CLE) was slightly down from last year, but the breadth of diagnostic products and innovations from China appears to be on the up. Hrishi Poola and Jon Chen discuss the moves China is making to become a generator of disruptive technologies and reports on the new products and the players emerging from this market
You may also be interested in...
NAD SWIFT Cases Get Swifter, More Frequent As Stakeholders Embrace Fast-Track Process
The BBB National Program Inc. expects to double the number of National Advertising Division SWIFT reviews completed in 2023 compared with last year as stakeholders grow more comfortable with the process. At its annual conference in Philadelphia 19-20 September, NAD said it is speeding up the time it takes to complete both SWIFT and standard track reviews.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.